Drugs / EGL-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06622486 | Sep 2024 → Jan 2027 expected | cancer | Egle Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGL-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06622486 ↗ |
| Route | Intravenous | “IV administration” NCT06622486 ↗ |